Cor Vasa 2024, 66(6):632-643 | DOI: 10.33678/cor.2024.084

(Antibiotic therapy of infective endocarditis. Recommended practice guaranteed by the Czech Society of Infectious Diseases, the Czech Society for Medical Microbiology, and the Czech Professional Society of Clinical Pharmacy)

Jiří Beneša, Pavla Paterováb, Lukáš Bauerc, Václav Musild, Marek Štefane
a Klinika infekčních nemocí, 3. lékařská fakulta Univerzity Karlovy a Fakultní nemocnice Bulovka, Praha, Česká republika
b Ústav klinické mikrobiologie, Lékařská fakulta Univerzity Karlovy a Fakultní nemocnice Hradec Králové, Hradec Králové, Česká republika
c Oddělení klinické farmacie, Fakultní nemocnice Bulovka, Praha, Česká republika
d Klinika dětských infekčních nemocí, Lékařská fakulta Masarykovy univerzity a Fakultní nemocnice Brno, Brno, Česká republika
e Klinika infekčních nemocí a cestovní medicíny, 2. lékařská fakulta Univerzity Karlovy a Fakultní nemocnice v Motole, Praha, Česká republika

Keywords: antibiotic regimes, antibiotic therapy, infective endocarditis, national guidelines, Platnost od: 1. 10. 2024. Plánovaná revize: 1. 10. 2029.,

Received: October 7, 2024; Accepted: October 13, 2024; Prepublished online: June 2, 2012; Published: December 20, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Beneš J, Paterová P, Bauer L, Musil V, Štefan M. (Antibiotic therapy of infective endocarditis. Recommended practice guaranteed by the Czech Society of Infectious Diseases, the Czech Society for Medical Microbiology, and the Czech Professional Society of Clinical Pharmacy). Cor Vasa. 2024;66(6):632-643. doi: 10.33678/cor.2024.084.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC Guidelines for the management of endocarditis. Eur Heart J 2023;44:3948-4042. Go to original source... Go to PubMed...
    2. Línková H, Marek D, Mates M, et al. Doporučený postup Evropské kardiologické společnosti pro léčbu endokarditidy 2023. Delgado V, Ajmone Marsan N, de Waha S, et al. Překlad zkráceného dokumentu vypracovaný Pracovní skupinou pro chlopenní a vrozené srdeční vady České kardiologické společnosti, Českou společností kardiovaskulární chirurgie ČLS JEP a Společností infekčního lékařství ČLS JEP. Cor Vasa 2024;66:112-168.
    3. Beneš J. Kritický komentář k textu "2023 ESC Guidelines for the Management of Endocarditis". Cor Vasa 2024;66:455-465. Go to original source...
    4. Holland TL, Bayer AS, Fowler VG Jr. Endocarditis and Endovascular Infections. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell's, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 9th ed. Elsevier 2024:1068-1108.
    5. Kaplan SL, Vallejo JG. Infective Endocarditis. In: Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 8th ed. Elsevier, 2019:256-270.
    6. Habib G, Erba PA, Iung B, et al. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC- -EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. Eur Heart J 2019;40:3222-3232. Go to original source... Go to PubMed...
    7. Thuny F, Habib G, Raoult D, Fournier PE. Endocarditis. In: Cohen J, Powderly WG, Opal SM, eds. Infectious Diseases, 4th ed. Elsevier, 2017:456-470. Go to original source...
    8. Beneš J. Antibiotika: systematika, vlastnosti, použití. Praha: Grada, 2018.
    9. Štefan M. Antibiotika v klinické praxi. 3rd ed. Praha: Galén, 2024.
    10. Grayson ML, ed. Kucers' the Use of Antibiotics, 6th ed. London: Edward Arnold Ltd. 2010. Go to original source...
    11. Neuville M, El-Helali N, Magalhaes E, et al. Systematic overdosing of oxa- and cloxacillin in severe infections treated in ICU: risk factors and side effects. Ann Intensive Care 2017;7:34. Go to original source... Go to PubMed...
    12. Chaudhry SB, Veve MP, Wagner JL. Cephalosporins: A Focus on Side Chains and β-Lactam Cross-Reactivity. Pharmacy (Basel) 2019;7:103. Go to original source... Go to PubMed...
    13. Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2020;71:1361-1364. Go to original source... Go to PubMed...
    14. Alvarez-Arango S, Ogunwole SM, Sequist TD, et al. Vancomycin Infusion Reaction - Moving beyond "Red Man Syndrome". N Engl J Med 2021;384:1283-1286. Go to original source... Go to PubMed...
    15. Martel TJ, Jamil RT, King KC. Vancomycin Flushing Syndrome. In: StatPearls. Online. Treasure Island (FL): StatPearls Publishing; 2024. Dostupné z: https://www.ncbi.nlm.nih.gov/books/NBK482506/. [citováno 2024-10-22].
    16. Dolan E, Hellinga R, London M, et al. Effect of Vancomycin Loading Doses on the Attainment of Target Trough Concentrations in Hospitalized Children. J Pediatr Pharmacol Ther 2020;25:423-430. Go to original source... Go to PubMed...
    17. Rozsypal H, Rozsypal L, Štefan M, Chrdle A. Kalkulačka k výpočtu dávkování gentamicinu a vancomycinu. Online. In: infektologie.cz. SIL ČLS JEP, 2008-2024. Dostupné z: https://infektologie.cz/zprava17-06.htm. [citováno 2024-10-22].
    18. Souhrn údajů o přípravku Daptomycin Reddy. Dostupné z: https://prehledy.sukl.cz/prehledy/v1/dokumenty/68727. [citováno 2024-10-22].
    19. Peiffer-Smadja N, Abbara S, Rizk N, et al. High-dose daptomycin in patients with infective endocarditis or sternal wound infections. Clin Microbiol Infect 2018;24:1106-1108. Go to original source... Go to PubMed...
    20. Jones TW, Jun AH, Michal JL, Olney WJ. High-Dose Daptomycin and Clinical Applications. Ann Pharmacother 2021;55:1363-1378. Go to original source... Go to PubMed...
    21. Souhrn údajů o přípravku Fomicyt. Dostupné z: https://prehledy.sukl.cz/prehledy/v1/dokumenty/11675. [citováno 2024-10-22].
    22. Lebeaux D, Fernández-Hidalgo N, Pilmis B, et al. Aminoglycosides for infective endocarditis: time to say goodbye? Clin Microbiol Infect 2020;26:723-728. Go to original source... Go to PubMed...
    23. Surveillance Atlas of Infectious Diseases. Dostupné na: http://atlas.ecdc.europa.eu/public/index.aspx. [citováno 2024-10-22].
    24. Graham JC, Gould FK. Role of aminoglycosides in the treatment of bacterial endocarditis. J Antimicrob Chemother 2002;49:437-444. Go to original source... Go to PubMed...
    25. Gavaldà J, Pahissa A, Almirante B, et al. Effect of gentamicin dosing interval on therapy of viridans streptococcal experimental endocarditis with gentamicin plus penicillin. Antimicrob Agents Chemother 1995;39:2098-2103. Go to original source... Go to PubMed...
    26. Sexton DJ, Tenenbaum MJ, Wilson WR, et al. Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group. Clin Infect Dis 1998;27:1470-1474. Go to original source... Go to PubMed...
    27. Starkel S, Goodberlet M, Schuler B, et al. Evaluating the incidence of acute kidney injury and gentamicin synergy dosing for endocarditis. JAC Antimicrob Resist 2023;6:dlad144. Go to original source... Go to PubMed...
    28. Houlihan HH, Stokes DP, Rybak MJ. Pharmacodynamics of vancomycin and ampicillin alone and in combination withgentamicin once daily or thrice daily against Enterococcus faecalis in an in vitro infection model. J Antimicrob Chemother 2000;46:79-86. Go to original source... Go to PubMed...
    29. Schwank S, Blaser J. Once- versus thrice-daily netilmicin combined with amoxicillin, penicillin, or vancomycin against Enterococcus faecalis in a pharmacodynamic in vitro model. Antimicrob Agents Chemother 1996;40:2258-2261. Go to original source... Go to PubMed...
    30. Lopez-Novoa JM, Quiros Y, Vicente L, et al. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int 2011;79:33-45. Go to original source... Go to PubMed...
    31. Beneš J, Džupová O, Šetina M, et al. Relapsing endocarditis caused by Enterococcus faecalis forming small colony variants. Scand J Infect Dis 2013;45:800-803. Go to original source... Go to PubMed...
    32. Picard W, Bazin F, Clouzeau B, et al. Propensity-based study of aminoglycoside nephrotoxicity in patients with severe sepsis or septic shock. Antimicrob Agents Chemother 2014;58:7468-7474. Go to original source... Go to PubMed...
    33. Bläckberg A, Falk L, Oldberg K, et al. Infective Endocarditis Due to Corynebacterium Species: Clinical Features and Antibiotic Resistance. Open Forum Infect Dis 2021;8:ofab055. Go to original source... Go to PubMed...
    34. Ioannou P, Ziogou A, Giannakodimos I, et al. Infective Endocarditis by Lactobacillus Species. A Narrative Review. Antibiotics (Basel) 2024;13:53. Go to original source... Go to PubMed...
    35. Kumaraswamy M, Do C, Sakoulas G, et al. Listeria monocytogenes endocarditis: case report, review of the literature, and laboratory evaluation of potential novel antibiotic synergies. Int J Antimicrob Agents 2018;51:468-478. Go to original source... Go to PubMed...
    36. Banzon JM, Rehm SJ, Gordon SM, et al. Propionibacterium acnes endocarditis: a case series. Clin Microbiol Infect 2017;23:396-399. Go to original source... Go to PubMed...
    37. Ioannou P, Baliou S, Papakitsou I, Kofteridis DP. Infective endocarditis by Actinomyces species: a systematic review. J Chemother 2023;35:87-94. Go to original source... Go to PubMed...
    38. McGee M, Brienesse S, Chong B, et al. Tropheryma whipplei Endocarditis: Case Presentation and Review of the Literature. Open Forum Infect Dis 2018;6:ofy330. Go to original source... Go to PubMed...
    39. Stuby J, Lardelli P, Thurnheer CM, et al. Trueperella pyogenes endocarditis in a Swiss farmer: a case report and review of the literature. BMC Infect Dis 2023;23:821. Go to original source... Go to PubMed...
    40. Beneš J, Kabelková M, Džupová O, et al. Infekční endokarditida: pacienti hospitalizovaní na Infekční klinice Fakultní nemocnice Bulovka v letech 1990-1999. Cor Vasa 2000;42:389-396.
    41. Pazdernik M, Baddour LM, Pelouch R. Infective endocarditis in the Czech Republic: eight years of experience at one of the country's largest medical centers. J Heart Valve Dis 2009;18:395-400.
    42. Beneš J, Baloun R, Džupová O. Endokarditidy 2007: Výsledky multicentrické studie o výskytu a vlastnostech infekční endokarditidy. Vnitr Lek 2011;57:147-154.
    43. Pazdernik M, Holicka M, Pelouch R, et al. Characteristics, management, and outcome of infective endocarditis in the Czech Republic: prospective data from the ESC EORP EURO- -ENDO registry. Bratisl Lek Listy 2021;122:95-100. Go to original source... Go to PubMed...
    44. Profylaxe infekční endokarditidy. Online. In: Česká kardiologická společnost. Dostupné z: https://www.kardio-cz.cz/zakladni-informace-ps-chlopenni-a-vrozene-srdecni-vady-v-dospelosti-271/. [citováno 2024-10-22].
    45. Štefan M, Dlouhý P. OPAT - ambulantní parenterální antimikrobiální terapie. Doporučený postup Společnosti infekčního lékařství ČLS JEP (17.5.2023). Online. Dostupné z: https://infektologie.cz/Standardy/OPAT_DP_2023_05_17-2.pdf. [citováno 2024-10-22].
    46. Bock M, Theut AM, van Hasselt JGC, et al. Attainment of Target Antibiotic Levels by Oral Treatment of Left-Sided Infective Endocarditis: A POET Substudy. Clin Infect Dis 2023;77:242-251. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes